Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Total IgE as marker in chronic spontaneous urticaria
|Filename||162. Altrichter et al., Total IgE marker CSU,AAIR 2021.pdf|
|Date added||March 15, 2021|
|Tags||biomarkers, chronic spontaneous urticaria, Cyclosporine, diagnosis, immunoglobulin E, omalizumab, receptor, therapeutics, urticaria|
|Authors||Altrichter, S., Fok, J. S., Jiao, Q., Kolkhir, P., Pyatilova, P., Moñino-Romero, S., Scheffel, J., Siebenhaar, F., Steinert, C., Terhorst-Molawi, D., Xiang, Y.-K., Church, M. K., and Maurer, M.|
|Citation||Altrichter, S., Fok, J. S., Jiao, Q., Kolkhir, P., Pyatilova, P., Moñino-Romero, S., Scheffel, J., Siebenhaar, F., Steinert, C., Terhorst-Molawi, D., Xiang, Y.-K., Church, M. K., and Maurer, M.: Total IgE as marker in chronic spontaneous urticaria. Allergy Asthma Immunol. Res. 2021: 13; 206-218.|
|IF||TBD (IF 2020: 5.76)|
|Publisher||Allergy Asthma Immunol. Res.|
Objective: Immunoglobulin E (IgE) and its receptor, FcɛRI, importantly contribute to the pathophysiology of chronic spontaneous urticaria (CSU). Recent findings point to a possible role of total IgE as a marker of CSU disease activity, endotypes, and responses to treatment. The evidence in support of total IgE included in the diagnostic workup of patients with CSU has not yet been reviewed.
Methods: Publications were searched via PubMed. The search terms used were “chronic urticaria” and “total IgE.” Studies were screened by titles and abstracts, and 141 were used in the review.
Results: CSU patients frequently had elevated total IgE serum levels (up to 50%), but normal or very low total IgE levels also occurred. High total IgE may represent high disease activity, longer disease duration, high chance of responding to omalizumab treatment, quick relapse after stopping omalizumab, and lower chance of responding to cyclosporine. Low IgE, in contrast, may suggest Type IIb autoimmune CSU, poor response to treatment with omalizumab and a better chance to benefits from cyclosporine treatment. Furthermore, IgE in different CSU cohorts may have different physicochemical properties that could explain differences in treatment responses to IgE-directed therapies.
Conclusion: The results of our review suggest that total IgE is a valuable marker for CSU, and we recommend its assessment in the routine diagnostic workup of CSU patients.
(Last update: 08.2021)
|Number of publications (original work and reviews) in peer-reviewed journals:||636|
|Number of original publications in peer-reviewed journals:||462|
|Number of reviews in peer-reviewed journals:||174|
|Cumulative IF of publications (original work & reviews) in peer-reviewed journals:||3834,12|
|Cumulative IF for original publications in peer-reviewed journals:||3043,14|
|Cumulative IF for reviews in peer-reviewed journals:||790,98|
|Citations, Hirsch index: (view on Web of Science)||26429|